<DOC>
	<DOCNO>NCT01431170</DOCNO>
	<brief_summary>The goal study evaluate application Besivance™ ( besifloxacin ophthalmic suspension , 0.6 % ) treat congenital nasolacrimal duct obstruction child . The hypothesis study Besivance™ safe effective current standard care treatment nasolacrimal duct obstruction child .</brief_summary>
	<brief_title>Safety Efficacy Study Besivance™ Treatment Congenital Nasolacrimal Duct Obstruction Children</brief_title>
	<detailed_description>The primary objective study evaluate safety efficacy Besivance™ antibiotic treatment congenital nasolacrimal duct obstruction infection child . The primary outcome measure change baseline physician rat scale Nasolacrimal Duct Obstruction ( NLDO ) infection follow-up visit # 2 ( Week 8 ) time treatment failure , early .</detailed_description>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>7- ( 3-aminohexahydro-1H-azepin-1-yl ) -8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Persons diagnose congenital Nasolacrimal Duct Obstruction ( NLDO ) infection Principal Investigator Both male female Persons age 1 12 month time diagnosis ( time diagnosis define Principal Investigator make clinical diagnosis . ) Persons receive antibiotic treatment NLDO infection 2 week past 4 week . Persons currently receive systemic antibiotic treatment discontinue . Persons ocular anomaly could potentially interfere interpretation study result . Persons prior nasolacrimal duct system procedures stenting probe . Persons previously participate clinical trial ( ) Besivance™ Persons participate clinical trial ( ) investigational agent ( ) within 30 day prior Baseline visit Persons chronic disease might interfere study participation</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>